Are you or someone you know living with #UlcerativeColitis (UC)? Take a moment to learn about the ROSETTA Study, a clinical trial of an investigational medicine. This study is currently enrolling. Learn more: https://bit.ly/3XJ7trL #ClinicalTrialEnrollment #ClinicalTrials
AnaptysBio
Biotechnology Research
San Diego, California 9,562 followers
Transforming patient health by delivering innovative immunology therapeutics.
About us
AnaptysBio ($ANAB) is a clinical-stage biotechnology company focused on transforming patient health by discovering and developing innovative immunology therapeutics. Our broad portfolio of immune cell modulators includes two checkpoint agonists in clinical-stage development. We are dedicated to making a difference in the lives of people living with autoimmune and inflammatory diseases.
- Website
-
https://www.anaptysbio.com
External link for AnaptysBio
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- San Diego, California
- Type
- Public Company
- Founded
- 2005
- Specialties
- Antibodies, Cancer immunotherapy, Inflammation, and Immunology
Locations
-
Primary
10770 Wateridge Circle
Suite 210
San Diego, California 92121, US
Employees at AnaptysBio
Updates
-
Team bonding at the ballpark! Last week, we celebrated #EmployeeAppreciationDay with a special outing to the San Diego Padres game. We’re grateful for all the memories made with this stellar Anaptys team. #WeAreAnaptysBio #TeamBonding #CompanyCulture
-
-
🎉 Join us in welcoming Annie (Xiaoping) Zhang, Cole Magliano, and Sloan Nino, PhD to Team Anaptys! We’re so glad to have these new colleagues on board and look forward to achieving great things together. #WeAreAnaptysBio #NewHires
-
Today, we announced a $100 million equity offering, led by long-standing Anaptys investor EcoR1 Capital, LLC, with participation from additional existing and new investors, including Sanofi. Anaptys intends to use the net proceeds of this offering primarily for general corporate purposes, which may include funding Phase 3 enabling activities of ANB032 and rosnilimab, working capital and general corporate purposes. The offering is expected to close on or about Aug. 15, 2024, subject to customary closing conditions. Read the full press release: https://lnkd.in/gXURxQqX $ANAB
-
Join us in recognizing Ramiro Ramirez, our dedicated Human Resources Coordinator who has been a vital member of our team since 2022. Ramiro, your hard work and contributions are greatly appreciated. Thank you! #WeAreAnaptysBio #CompanyCulture
-
#ICYMI: We announced the enrollment completion of the Phase 2b ARISE-AD Study evaluating our investigational BTLA agonist in people living with #AtopicDermatitis. Our thanks to all who have helped us reach this milestone in our ongoing work to deliver innovative immunology therapeutics to those living with #Autoimmune and #InflammatoryDiseases. $ANAB #ClinicalTrial #ClinicalTrialEnrollment
-
-
Today, we announced our #Q2 earnings and provided an update on our work to develop immune cell modulators for patients living with #Autoimmune and #InflammatoryDiseases. Read our full announcement: https://bit.ly/46Hqxcw #Q2Earnings $ANAB
-
At the heart of our vision to transform patient health through innovative immunology therapeutics are three core values that guide our actions. Learn more: https://lnkd.in/g5yXUb66 #WeAreAnaptysBio #CompanyCulture #CompanyValues
-
It doesn’t take a scientist to understand our science! "Short Takes on Deep Science” offers bite-sized, expert perspectives on the latest in immune cell modulation and therapeutic innovation for #Autoimmune and #InflammatoryDiseases. Listen now at https://lnkd.in/eVM7G9DQ
-
Did you know an estimated four in 10 people living with #RheumatoidArthritis (RA) do not achieve disease remission with the current standard of care? Learn more about RA and our ongoing research evaluating a potential new treatment option.